Clinical and Experimental Dermatology最新文献_第2页

A young lady with myopathy, neuropathy and retiform purpura. 一位患有肌病、神经病和视网膜紫癜的年轻女士。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2026-04-28 DOI: 10.1093/ced/llag190

Muhammed Razmi T, P Shihabudheen, Arun Somasundaram, Shamsudheen Moideen, K P Aravindan, T P Afra, Praveen Kumar Raghunath, Sheetanshu Kumar

引用次数: 0

Possible involvement of IL-31 in pruriginosa-type recessive dystrophic epidermolysis bullosa: a nemolizumab-responsive case. IL-31可能参与pruriginsa型隐性营养不良大疱性表皮松解症：一个耐单抗反应的病例。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2026-04-28 DOI: 10.1093/ced/llag186

Nana Ebi, Toshiaki Kogame, Akemi Ishida-Yamamoto, Eijiro Akasaka, Kenji Kabashima

引用次数: 0

Discovery of a Novel Hemizygous c.375_389del Variant in the MBTPS2TPS2 Gene in a Male Patient. 一名男性患者MBTPS2TPS2基因新半合子c.375_389del变异的发现

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2026-04-28 DOI: 10.1093/ced/llag189

Yunus Ozcan, Sevgi Ilcin, Mustafa Dogan, Belkız Uyar

引用次数: 0

Comment on 'Recurrent morphoeic basal cell carcinoma with metastatic progression in a 34-years-old patient: a case report'. 评论“一例34岁患者复发性形态型基底细胞癌伴转移进展：1例报告”。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2026-04-28 DOI: 10.1093/ced/llag184

Dursun Turkmen, Rafet Ozbey

引用次数: 0

Dupilumab for Immunological Eruption of Aging in Older Patients: Real-World Effectiveness, Safety, and Th2-skewed Immunologic Features. Dupilumab用于老年患者的免疫性衰老爆发：真实世界的有效性，安全性和th2偏斜免疫特征。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2026-04-27 DOI: 10.1093/ced/llag188

Jiyoon Baek, Jin Hyun Jang, Hyun Ji Kang, Joo Yeon Ko, Joung Soo Kim, Younghye Kim, Mihn-Sook Jue

引用次数: 0

Real-world efficacy and safety of Sonidegib in Locally Advanced and Multiple Basal Cell Carcinomas: A Monocentric Prospective Observational Study. 索地吉治疗局部晚期和多发性基底细胞癌的疗效和安全性：一项单中心前瞻性观察研究

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2026-04-25 DOI: 10.1093/ced/llag157

Chiara Del Re, Vincenzo Filastro, Gaia Fasano, Giancarlo Valenti, Pierfrancesco De Giacomo

{"title":"Real-world efficacy and safety of Sonidegib in Locally Advanced and Multiple Basal Cell Carcinomas: A Monocentric Prospective Observational Study.","authors":"Chiara Del Re, Vincenzo Filastro, Gaia Fasano, Giancarlo Valenti, Pierfrancesco De Giacomo","doi":"10.1093/ced/llag157","DOIUrl":"https://doi.org/10.1093/ced/llag157","url":null,"abstract":"This monocentric study evaluated the real-world efficacy and safety of Sonidegib in 17 patients with locally advanced or multiple basal cell carcinomas (laBCC/mBCC), characterized by complex surgical histories and comorbidities. The objective response rate was 52.9% of patients achieved Complete Response, 29.4% Partial Response, and 17.7% Stable Disease, with no documented progression during treatment (mean 7.3 months). Sonidegib showed significant efficacy in multiple BCCs, with a mean reduction of 3.89 lesions per patient. Key findings indicate prior surgery correlates with poorer response, while Sonidegib effectively 'clears the field' of subclinical lesions. The safety profile was favorable, with predominantly mild and manageable adverse events. Despite the limited sample size, our findings confirm the significant efficacy of Sonidegib in a frail, pre-treated population with multiple comorbidities. This study supports its use as a valuable therapeutic strategy for complex patients with high tumor burden or those ineligible for further surgery.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Misinformation is Present in Popular Social Media Content About Melanoma. 流行的社交媒体内容中存在关于黑色素瘤的错误信息。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2026-04-25 DOI: 10.1093/ced/llag181

Rhys L Richmond, Michal Kidacki, Goran Micevic

引用次数: 0

Combination long pulsed Nd:YAG and pulsed-dye laser therapy with intralesional triamcinolone for treatment-resistant nasal lupus pernio: a case report. 长脉冲Nd:YAG与脉冲染料激光联合局部曲安奈德治疗难治性鼻部狼疮1例。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2026-04-25 DOI: 10.1093/ced/llag192

Monica Narula, Belinda Welsh

引用次数: 0

Deucravacitinib in Moderate-to-Severe Plaque Psoriasis: A Real-World Study of Effectiveness and Safety in Clinical Practice. Deucravacitinib治疗中重度斑块性银屑病：临床实践中有效性和安全性的真实世界研究

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2026-04-25 DOI: 10.1093/ced/llag187

Angelo Ruggiero, Raffaele Mozzillo, Mario Cordedda, Elisa Camela, Renato Zanchini, Paola Colasanti, Orlando Zagaria

{"title":"Deucravacitinib in Moderate-to-Severe Plaque Psoriasis: A Real-World Study of Effectiveness and Safety in Clinical Practice.","authors":"Angelo Ruggiero, Raffaele Mozzillo, Mario Cordedda, Elisa Camela, Renato Zanchini, Paola Colasanti, Orlando Zagaria","doi":"10.1093/ced/llag187","DOIUrl":"https://doi.org/10.1093/ced/llag187","url":null,"abstract":"Background: Deucravacitinib, an oral TYK2 inhibitor, has demonstrated efficacy and safety in phase III clinical trials for moderate-to-severe plaque psoriasis. However, real-world evidence remains limited.Objectives: To evaluate the effectiveness and safety of deucravacitinib in adult patients with moderate-to-severe plaque psoriasis treated in routine clinical practice.Methods: We conducted a retrospective, single-center, real-world observational study. Consecutive adult patients with moderate-to-severe plaque psoriasis who initiated deucravacitinib between December 2024 and December 2025 were retrospectively identified. At each follow up PASI, DLQI, BSA, NRS pruritus. PASI75, PASI90, and PASI100 response rates were also evaluated. Safety was assessed through adverse event reporting and routine laboratory monitoring.Results: A total of 46 patients completed the 24-week follow-up and were included in the study. Mean PASI decreased from 12.5±3.1 at baseline to 3.2±2.1 at Week 24 (p < 0.001), while mean BSA decreased from 18.0±6.5% to 5.0±3.6% (p< 0.001). NRS pruritus and DLQI also improved significantly over time (both p < 0.001). PASI 75 was achieved by 69.6% of patients at Week 24, while PASI 90 and PASI 100 were achieved by 54.3% and 32.6%, respectively. No serious adverse events or clinically relevant laboratory abnormalities were observed. Acne was the most frequent adverse event, occurring in 4 patients (8.7%), and was mild in all cases.Conclusions: In this real-world study, deucravacitinib showed significant and sustained effectiveness, together with a favorable safety profile, in patients with moderate-to-severe plaque psoriasis. These findings support its role as an effective oral targeted therapy in routine clinical practice.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chromoblastomycosis: a contemporary review of a neglected disease. 成色菌病：一种被忽视疾病的当代回顾。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2026-04-24 DOI: 10.1093/ced/llaf201

William Tuckwell, Paul D Yesudian, David Chandler

引用次数: 0